參考文獻 |
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015; 65(2): 87-108.
2. Chiang, H. S., Guo, H. R., Hong, C. L., Lin, S. M., Lee, E. F. The incidence of bladder cancer in the black foot disease endemic area in Taiwan. British Journal of Urology, 1993; 71: 274-278.
3. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology, 2005; 23(21): 4602-4608.
4. 國泰醫院,癌症資訊網"膀胱癌簡介" https://www.cgh.org.tw/tw/content/depart/cancer/intropage12.html
5. 陳沛輝,亞東醫院,相關醫學資訊"膀胱癌預防" http://depart.femh.org.tw/indge/l2_9.aspx
6. 台灣泌尿腫瘤協會, "膀胱癌之診斷" , http://www.tuoa.tw/?p=19
7. 汪徽五, 周., 以奈米微胞做為傳輸化療藥物的設計考量及國際醫藥法規 管理新進展. RegMed, 2015; 53.
8. M. C. Metts, J. C. Metts, S. J. Milito, C. R. Thomas, Jr. Bladder cancer: a review of diagnosis and management. Journal of the National Medical Association, 2000; 92(6): 285-294.
9. Sumit Isharwal , Badrinath Konety. Non-muscle invasive bladder cancer risk stratification. Indian Journal of Urology, 2015; 31(4): 289–296.
10. National Cancer Institute (NCI), " Stages of Bladder Cancer" , https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq#section/_109
11. Uptodate資料庫, " WHAT IS INVASIVE BLADDER CANCER? "
,https://www.uptodate.com/contents/bladder-cancer-treatment-invasive-cancer-beyond-the-basics
12. Hooson J, Hicks RM, Grasso P, Chowaniec J. Ortho-toluene sulphonamide and saccharin in the promotion of bladder cancer in the rat. British Journal of Cancer, 1980; 42(1): 129-147.
13. Price JM, Biava CG, Oser BL, Vogin EE, Steinfeld J, Ley HL. Bladder tumors in rats fed cyclohexylamine or high doses of a mixture of cyclamate and saccharin. Science, 1970; 167(3921): 1131-1132.
14. KERR WK, BARKIN M, LEVERS PE, WOO SK, MENCZYK Z. The Effect of Cigarette Smoking on Bladder Carcinogens in Man. Canadian Medical Association Journal, 1965; 93: 1-7 .
15. Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu, Elizabeth Ward. Cancer Statistics, 2010. CA: a cancer journal for clinicians, 2010; 60: 277-300.
16. American Cancer Society, " Intravesical Therapy for Bladder Cancer" ,https://www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html
17. Tan LB, Lin LM, Huang CH, Chiang CP, Chien CH, Pan CC. Antigenic detection and prognosis of patients with transitional cell carcinoma of the urinary bladder. Urologia Internationalis, 1989; 44: 264-271.
18. Henderson, T.A., Morries, L.D. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatric Disease and Treatment, 2015; 11: 2191-2208.
19. Cheng, L., Wang, C., Feng, L., Yang, K., Liu, Z. Functional nanomaterials for phototherapies of cancer. Chemical Reviews, 2014; 114: 10869-10939.
20. Rui, L.-L., H.-L. Cao, Y.-D. Xue, L.-C. Liu, L. Xu, Y. Gao, W.-A. Zhang. Functional organic nanoparticles for photodynamic therapy. Chinese Chemical Letters, 2016; 27(8): 1412-1420.
21. Tong, L., Y. Zhao, T.B. Huff, M.N. Hansen, A. Wei and J.-X. Cheng. Gold Nanorods Mediate Tumor Cell Death by Compromising Membrane Integrity. Advanced materials (Deerfield Beach, Florida), 2007; 19: 3136-3141.
22. Hildebrandt, B., P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa, T. Kerner, R. Felix and H. Riess. The cellular and molecular basis of hyperthermia. Critical Reviews in Oncology / Hematology, 2002; 43(1): 33-56.
23. Jang, B., J.-Y. Park, C.-H. Tung, I.-H. Kim, Y. Choi. Gold Nanorod?Photosensitizer Complex for Near-Infrared Fluorescence Imaging and Photodynamic/Photothermal Therapy In Vivo. ACS Nano, 2011; 5(2): 1086-1094.
24. Matylevitch NP, Schuschereba ST, Mata JR, Gilligan GR, Lawlor DF, Goodwin CW, Bowman PD. Apoptosis and accidental cell death in cultured human keratinocytes after thermal injury. The American journal of pathology, 1998; 153(2): 567-577.
25. Alla Bucharskaya, Galina Maslyakova, Georgy Terentyuk, Alexander Yakunin, Yuri Avetisyan, Olga Bibikova, Elena Tuchina, Boris Khlebtsov, Nikolai Khlebtsov, Valery Tuchin. Towards Effective Photothermal/Photodynamic Treatment Using Plasmonic Gold Nanoparticles. International Journal of Molecular Sciences , 2016; 17(8).
26. Henderson, B.W., T.J. Dougherty. HOW DOES PHOTODYNAMIC THERAPY WORK? Photochemistry and Photobiology, 1992; 55(1): 145-157.
27. Athar M, Elmets CA, Bickers DR, Mukhtar H. A novel mechanism for the generation of superoxide anions in hematoporphyrin derivative-mediated cutaneous photosensitization. Activation of the xanthine oxidase pathway. Journal of Clinical Investigation, 1989; 83(4): 1137-43.
28. Dolmans DE., Fukumura D., Jain RK. Photodynamic therapy for cancer. Nature Reviews Cancer, 2003; 3(5): 380-387.
29. Allison, R.R., K. Moghissi. Photodynamic Therapy (PDT): PDT Mechanisms. Clinical Endoscopy, 2013; 46(1): 24-29.
30. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. British journal of cancer, 1994; 69(3): 605.
31. ?ivil? Luk?ien?. Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment. Medicina, 2003; 39(12): 1137-1150.
32. Jie Yu, Mohammad A. Yaseen, Bahman Anvari, Michael S. Wong. Synthesis of near-infrared-absorbing nanoparticle-assembled capsules. Chemistry of materials, 2007; 19(6): 1277-1284.
33. Jean Marie Devoisselle, Sylvie Soulie Begu, Serge R. Mordon, Thomas Desmettre, H. Maillols. Fluorescence properties of indocyanin green-part 1: in-vitro study with micelles and liposomes. SPIE - the international society for optics and photonics, 1997; 2980: 453-460.
34. Philip, R., Penzkofer, Alfons, Baumler, W., Szeimies, R., Abels, C. Absorption and fluorescence spectroscopic investigation of indocyanine green. Journal of Photochemistry and Photobiology A: Chemistry, 1996; 96: 137–148.
35. Engel E, Schraml R, Maisch T, Kobuch K, Konig B, Szeimies RM, Hillenkamp J, Baumler W, Vasold R. Light-induced decomposition of indocyanine green. Investigative Ophthalmology & Visual Science, 2008; 49(5): 1777-1783.
36. Miwa, M. The principle of ICG fluorescence method. Open Surgical Oncology Journal, 2010; 2: 26-28.
37. Mustafa Kemal Ruhi, Ay?e Ak, Murat Gulsoy. Dose-dependent photochemical/photothermal toxicity of indocyanine green-based therapy on three different cancer cell lines. Photodiagnosis and Photodynamic Therapy, 2018; 21: 334-343
38. Nonami T, Nakao A, Kurokawa T, Inagaki H, Matsushita Y, Sakamoto J, Takagi H. Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Journal of Hepato-Gastroenterology, 1999; 46(27): 1669-1672.
39. Camille Giraudeau, Albert Moussaron, Aurelie Stallivieri, Serge Mordon, Celine Frochot. Indocyanine green: photosensitizer or chromophore? Still a debate. Current Medicinal Chemistry, 2014; 21(16): 1871–1897.
40. Saxena V, Sadoqi M, Shao J. Degradation kinetics of indocyanine green in aqueous solution. Journal of Pharmaceutical Sciences, 2003; 92(10): 2090–2097.
41. Shemesh CS, Moshkelani D, Zhang H. Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer . Pharmaceutical Research, 2015; 32: 1604–1614.
42. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. Journal of Neuro-Oncology, 2008; 86: 165–172.
43. Mundra V, Peng Y, Rana S, Natarajan A, Mahato RI. Micellar formulation of indocyanine green for phototherapy of melanoma. Journal of Controlled Release, 2015; 220: p.130–140.
44. Ishizawa T1, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, Hasegawa K, Beck Y, Fukayama M, Kokudo N. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer, 2009; 115(11): 2491-2504.
45. Kaibori M, Matsui K, Ishizaki M, Iida H, Sakaguchi T, Tsuda T, Okumura T, Inoue K, Shimada S, Ohtsubo S, Kusano M, Ikehara Y, Ozeki E, Kitawaki T, Kon M. Evaluation of fluorescence imaging with indocyanine green in hepatocellular carcinoma. Cancer Imaging, 2016; 6(16).
46. Zhou, J.F., M.P. Chin, S.A. Schafer. Aggregation and degradation of indocyanine green. International Society for Optics and Photonics, 1994; 2128: 495-505.
47. Landsman ML, Kwant G, Mook GA, Zijlstra WG. Light-absorbing properties, stability, and spectral stabilization of indocyanine green. Journal of applied physiology, 1976; 40(4): 575-583.
48. Holzer W, Mauerer M, Penzkofer A, Szeimies RM, Abels C, Landthaler M, Baumler W. Photostability and thermal stability of indocyanine green. Journal of Photochemistry and Photobiology B: Biology, 1998; 47: 155–164.
49. Cherrick, G.R., S. W. Stein, C.M. Leevy, C.S. Davidson. INDOCYANINE GREEN: OBSERVATIONS ON ITS PHYSICAL PROPERTIES, PLASMA DECAY, AND HEPATIC EXTRACTION. Journal of Clinical Investigation, 1960; 39(4): 592-600.
50. Mordon S, Devoisselle JM, Soulie-Begu S, Desmettre T. Indocyanine green: physicochemical factors affecting its fluorescencein vivo. Microvascular research, 1998; 55(2): 146-152.
51. van den Biesen PR, Jongsma FH, Tangelder GJ, Slaaf DW. Yield of fluorescence from indocyanine green in plasma and flowing blood. Annals of biomedical engineering, 1995; 23(4): 475-481.
52. Desmettre, T., J. Devoisselle, S. Mordon. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Survey of ophthalmology, 2000; 45(1): 15-27.
53. Oradell, N. J. Physicians′ Desk Reference (Medical Economics Company), 1975: 642-643.
54. Jaap Verweij, Herbert M Pinedo. Mitomycin C: Mechanism of action,usefulness and limitations. Anti-Cancer Drugs, 1990; 1: 5–13
55. Palom, Y., Suresh Kumar, G., Tang, L.Q., Paz, M.M., Musser, S.M., Rockwell, S., Tomasz, M. Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chemical Research in Toxicology, 2002, 15(11): 1398-1406.
56. Workman, P., Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer and Metastasis Reviews, 1993, 12: 73-82.
57. Verwey, J., de Vries, J., Pinedo, H.M. Mitomycin C-induced renal toxicity, a dose-dependent side effect?. European Journal of Cancer and Clinical Oncology, 1987; 23: 195-199.
58. J.G. Riess. Oxygen carriers ("blood substitutes")--raison d′etre, chemistry, and some physiology. Chemical Reviews, 2001; 101(9): 2797–2920.
59. M.P. Krafft, J.G. Riess, J.G. Weers. in: S. Benita (Ed.). Submicron Emulsions in Drug Targeting and Delivery, Harwood. Amsterdam, 1998: 235–333.
60. Kenneth C. Lowe. Perfluorochemical respiratory gas carriers: benefits to cell culture systems. Journal of Fluorine Chemistry, 2002; 118: 19–26.
61. Kenneth C. Lowe. Engineering blood: synthetic substitutes from fluorinated compound. Journal of Tissue Engineering, 2003; 9(3): 389-399.
62. Cabrales, P., J.C. Briceno. Delaying blood transfusion in experimental acute anemia with a perfluorocarbon emulsion. The Journal of the American Society of Anesthesiologists, 2011; 114(4): 901-911.
63. Fraker CA1, Mendez AJ, Inverardi L, Ricordi C, Stabler CL. Optimization of perfluoro nano-scale emulsions: The importance of particle size for enhanced oxygen transfer in biomedical applications. Colloids and Surfaces B: Biointerfaces, 2012; 98: 26-35.
64. Spiess, B.D. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics. Journal of Applied Physiology, 2009; 106(4): 1444-1452.
65. Diaz-Lopez, R., N. Tsapis, E. Fattal. Liquid perfluorocarbons as contrast agents for ultrasonography and 19F-MRI. Pharmaceutical research, 2010. 27(1): 1-16.
66. Kornmann LM, Reesink KD, Reneman RS, Hoeks AP. Critical appraisal of targeted ultrasound contrast agents for molecular imaging in large arteries. Ultrasound in medicine & biology, 2010. 36(2): 181-191.
67. Fabiilli ML, Lee JA, Kripfgans OD, Carson PL, Fowlkes JB. Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions. Pharmaceutical research, 2010; 27(12): 2753-2765.
68. Rapoport N, Nam KH, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X, Kim T, Shea J, Scaife C, Parker DL, Jeong EK, Kennedy AM. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. Journal of Controlled Release, 2011; 153(1): 4-15.
69. Shiraishi K, Endoh R, Furuhata H, Nishihara M, Suzuki R, Maruyama K, Oda Y, Jo J, Tabata Y, Yamamoto J, Yokoyama M. A facile preparation method of a PFC-containing nano-sized emulsion for theranostics of solid tumors. International journal of pharmaceutics, 2011; 421(2): 379-387.
70. F.S.Moolman, H.Rolfes, S.W.van derMerwe, W.W.Focke. Optimization of perfluorocarbon emulsion properties for enhancing oxygen mass transfer in a bio-artificial liver support system. Biochemical engineering journal, 2004; 19(3): 237-250.
71. Khattak SF, Chin KS, Bhatia SR, Roberts SC. Enhancing oxygen tension and cellular function in alginate cell encapsulation devices through the use of perfluorocarbons. Biotechnology and bioengineering, 2007; 96(1): 156-166.
72. Maillard E, Juszczak MT, Langlois A, Kleiss C, Sencier MC, Bietiger W, Sanchez-Dominguez M, Krafft MP, Johnson PR, Pinget M, Sigrist S. Perfluorocarbon emulsions prevent hypoxia of pancreatic β-cells. Cell transplantation, 2012; 21(4): 657-669.
73. McMILLAN, J.D., D.I. Wang, Enhanced Oxygen Transfer Using Oil?in?Water Dispersionsa. Annals of the New York Academy of Sciences, 1987; 506(1): 569-582.
74. Ju, L.K., J.F. Lee, W.B. Armiger. Enhancing oxygen transfer in bioreactors by perfluorocarbon emulsions. Biotechnology Progress, 1991; 7(4): 323-329.
75. K.C. Lowe, M.R. Davey, J.B. Power, Perfluorochemicals: their applications and benefits to cell culture. Trends in Biotechnology, 1998; 16(6): 272–277.
76. Ruchir Bhomia, Vivek Trivedi, John C. Mitchell, Nichola J. Coleman, Martin J. Snowden. Effect of Pressure on the Melting Point of Pluronics in Pressurized Carbon Dioxide. Industrial & Engineering Chemistry Research, 2014; 53: 10820-10825.
77. Yang M., Lai S. K., Wang Y., Zhong W., Happe C., Zhang M., Fu J., Hanes J. Biodegradable Nanoparticles Composed Entirely of Safe Materials That Rapidly Penetrate Human Mucus. Angewandte Chemie International Edition in English, 2011; 50(11): 2597.
78. Wei H., Zhuo R.-X., Zhang X.-Z. Design and Development of Polymeric Micelles with Cleavable Links for Intracellular Drug Delivery. Progress in Polymer Science, 2014; 38: 503.
79. Kumari A., Yadav S. K., Yadav S. C. Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems. Colloids and Surfaces B: Biointerfaces, 2010; 75: 1.
80. Kabanov. A., Batrakova. E., Alakhov. V. Pluronic Block Copolymers as Novel Polymer Therapeutics for Drug and Gene Delivery. Journal of Controlled Release, 2002; 82: 189.
81. S. D. Carrigan, G. Scott, M. Tabrizian. Real-Time QCM-D Immunoassay through Oriented Antibody Immobilization Using Cross-Linked Hydrogel Biointerfaces. Langmuir, 2005; 21: 5966-5973
82. Chulhun Park , Chau Le-Ngoc Vo , Taehee Kang , Euichaul Oh , Beom-Jin Lee. New method and characterization of self-assembled gelatin–oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction. European Journal of Pharmaceutics and Biopharmaceutics, 2015; 89: 365-373
83. Kolovskaya OS, Zamay TN, Belyanina IV, Karlova E, Garanzha I, Aleksandrovsky AS, Kirichenko A, Dubynina AV, Sokolov AE, Zamay GS, Glazyrin YE, Zamay S, Ivanchenko T, Chanchikova N, Tokarev N, Shepelevich N, Ozerskaya A, Badrin E, Belugin K, Belkin S, Zabluda V, Gargaun A, Berezovski MV, Kichkailo AS. Aptamer-Targeted Plasmonic Photothermal Therapy of Cancer. Molecular Therapy: Nucleic Acids, 2017; 9: 12-21
84. D. Jaque, L. Martinez Maestro, B. del Rosal, P. Haro-Gonzalez, A. Benayas, J. L. Plaza, E. Martin Rodrigueza, J. Garcia Sole. Nanoparticles for photothermal therapies. Nanoscale, 2014; 6(16) : 9494-9530.
85. Friedrich, M.G., Pichlmeier, U., Schwaibold, H., Conrad, S., Huland, H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. European Urology, 2007; 52: 1123-1129.
86. Juan L. Vasquez , Julie Gehl , Gregers G. Hermann, Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line:A potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry, 2012; 88: 127-133 |